Click Holdings Limited (NASDAQ:CLIK) Sees Significant Decline in Short Interest

Click Holdings Limited (NASDAQ:CLIK) was the target of a significant decrease in short interest in the month of May. As of May 29th, there was short interest totaling 50,211 shares, a decrease of 48.6% from the May 14th total of 97,673 shares. Currently, 4.4% of the shares of the stock are sold short. Based on an average trading volume of 1,195,878 shares, the short-interest ratio is presently 0.0 days.

Institutional Trading of Click

A hedge fund recently bought a new stake in Click stock. Renaissance Technologies LLC bought a new position in shares of Click Holdings Limited (NASDAQ:CLIK) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 14,200 shares of the company’s stock, valued at approximately $25,000. Renaissance Technologies LLC owned approximately 1.23% of Click as of its most recent SEC filing.

Click Stock Down 1.9%

Shares of CLIK stock traded down $0.03 on Friday, reaching $1.58. 2,090,395 shares of the company were exchanged, compared to its average volume of 2,789,769. The business has a 50-day moving average price of $2.12 and a 200 day moving average price of $3.60. Click has a 1 year low of $1.32 and a 1 year high of $15.90.

Click (NASDAQ:CLIK) last released its earnings results on Monday, May 11th. The company reported $0.10 EPS for the quarter. The company had revenue of $3.79 million for the quarter.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on CLIK shares. Weiss Ratings reiterated a “sell (d)” rating on shares of Click in a research report on Friday, March 27th. Wall Street Zen upgraded shares of Click to a “hold” rating in a research report on Saturday. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

About Click

Click Therapeutics, Inc (NASDAQ: CLIK) is a clinical-stage digital therapeutics company developing software-based treatments for neurological, psychiatric and chronic diseases. Its platform delivers prescription digital therapies via mobile and web applications, combining evidence-based cognitive behavioral interventions, digital monitoring tools and patient engagement techniques. Click’s approach is designed to complement or extend traditional pharmacological and behavioral treatments for conditions such as major depressive disorder, insomnia and tobacco use disorder.

Founded in 2014, Click has progressed multiple programs through randomized controlled trials and regulatory review.